MedTrace Logo

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

NCT05116891 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-07-03

No results posted yet for this study

Summary

This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).

Conditions

Interventions

DRUG

CAN04 (nadunolimab)

FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP

DRUG

mFOLFOX

mFOLFOX/CAN04

DRUG

DTX

DTX/CAN04

DRUG

G/C

G/C/CAN04

Sponsors & Collaborators

  • Cantargia AB

    lead INDUSTRY

Principal Investigators

  • Ignacio Garcia-Ribas, MD, PhD · Cantargia AB

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2023-06-23
Completion
2023-06-23

Countries

  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116891 on ClinicalTrials.gov